CLINICAL_TRIALS
trial_result
· 2026-02-13
Clinical Trial Update: An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis [Phase 2]
Summary
An open-label Phase 2 study evaluating the efficacy and safety of nemolizumab in systemic sclerosis has completed. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Maruho Co., Ltd. | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2026-02-13